Antiviral Therapies
Some advances have been made in devising antiviral therapy for LCMV, predominantly because of the constant negative impacts faced in some populations. The general antiviral, Ribavirin, has been given but with only limited success. In contrast, pyrazinecarboxamide derivative favipiravir proved very beneficial in preclinical models because of its strong antiviral effects by means of survival and considerably reduced viral loads.
Immunotherapies
Immunotherapeutic efforts have also been directed against those specific monoclonal antibodies which neutralize at the same level as the virus. They are, for instance, meant to block some of the protective mechanisms which are normally utilized by the host to defend itself against LCMV. Human monoclonal antibodies that were developed against Lassa virus glycoproteins have been shown to cross-react with LCMV and thus may be of therapeutic value.